Met Life Investment Management, LLC Viking Therapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $18 Billion
- Q4 2024
A detailed history of Met Life Investment Management, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 6,550 shares of VKTX stock, worth $185,692. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,550
Previous 6,629
1.19%
Holding current value
$185,692
Previous $419,000
37.23%
% of portfolio
0.0%
Previous 0.0%
Shares
47 transactions
Others Institutions Holding VKTX
# of Institutions
468Shares Held
65.8MCall Options Held
5.84MPut Options Held
3.76M-
Vanguard Group Inc Valley Forge, PA10.2MShares$288 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$171 Million0.01% of portfolio
-
State Street Corp Boston, MA4.93MShares$140 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.59MShares$73.5 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.16MShares$61.2 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.17B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...